Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of statin intolerance~* Diagnosis of Coronary Artery Disease (CAD)~* Diagnosis of hypercholesterolemia~* Stable weight for \> 6 weeks~Exclusion Criteria:~* Significant health problems in the recent past (≤24 weeks) including heart attack, heart surgery, heart failure, uncontrolled hypothyroidism, blood disorders, digestive problems, disease of central nervous system, cancer, liver or renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 1 mL placebo saline, weekly subcutaneous injections for 26 weeks
- Mipomersen (Type: EXPERIMENTAL): 200 mg (1 mL), weekly subcutaneous injections for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).